Here is the design of a clinical trial:

Official Title: An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Included conditions:
- COVID-19

Study Armgroups:
- {'label': 'Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Hydroxychloroquine', 'Drug: Lopinavir / Ritonavir', 'Drug: Interferon Beta-1A']}
- {'label': 'Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Hydroxychloroquine', 'Drug: Lopinavir / Ritonavir', 'Drug: Interferon Beta-1B']}
- {'label': 'Control group: hydroxychloroquine + Lopinavir / Ritonavir', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: Hydroxychloroquine', 'Drug: Lopinavir / Ritonavir']}

Interventions:
- {'type': 'DRUG', 'name': 'Hydroxychloroquine', 'description': 'This Drug will be used in all arms.', 'armGroupLabels': ['Control group: hydroxychloroquine + Lopinavir / Ritonavir', 'Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a', 'Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b']}
- {'type': 'DRUG', 'name': 'Lopinavir / Ritonavir', 'description': 'This Drug will be used in all arms.', 'armGroupLabels': ['Control group: hydroxychloroquine + Lopinavir / Ritonavir', 'Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a', 'Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b']}
- {'type': 'DRUG', 'name': 'Interferon Beta-1A', 'description': 'This drug will be only used in Arm 1.', 'armGroupLabels': ['Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a']}
- {'type': 'DRUG', 'name': 'Interferon Beta-1B', 'description': 'This drug will be only used in Arm 2.', 'armGroupLabels': ['Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b']}

Primary Outcomes:
- {'measure': 'Time to clinical improvement', 'description': 'Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R\\&D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.', 'timeFrame': 'From date of randomization until 14 days later.'}

Please estimate the sample size based on the assumption: 
Not explicitly stated in the provided paragraph.
Numbers to be Randomized (Sample Size)
          Of the 60 patients who underwent randomization, 20 patients were assigned to receive Interferon beta-1a, 20 patients were assigned to receive Interferon beta 1b plus standard care and the rest of patients were assigned to receive the standard care alone.